fda glp-1 compounding crackdown october 2025 ESCALATES: 30 telehealth companies hit with warning letters for false claims on compounded drugs. The agency accuses firms of misleading consumers by implying unapproved compounded versions match FDA-approved medications FDA Intensifies Crackdown on GLP-1

This lack of regulation is a significant concern

Furthermore, WB analysis was conducted on extracts from the aortas of aging mice, showing consistent results with in vitro experiments: increased expression of p-P53 and decreased expression of total P53 after FOXO4-DRI treatment

What is measured in these rats and mice (and occasionally in small groups of human volunteers) is often not a hard endpoint like muscle strength or weight loss, but surrogate biomarkers: molecules in the blood that have an indirect link to a hard endpoint

Thus, they are a potential and sensitive source of non-invasive diagnostic markers

And crucially, how to nurture it